Patients who should receive guideline-recommended genetic testing are often missed due to complex guidelines, discretionary referral practices, inefficient charting processes and siloed data and care teams. Consequently, patients who are candidates for precision therapeutics are overlooked and families cannot characterize patterns of heritability and risk, resulting in suboptimal treatments and strategies.
OncoLens Advanced Patient ID utilizes Large Language Models and AI to identify patients who have not yet received guideline-recommended testing needed to detect germline mutations as well as somatic and/or acquired mutations like ESR1, etc. Consolidated reports of patients who may need additional testing are generated by OncoLens and delivered directly to the care team, reducing review time by ≈ 75%. By proactively and automatically identifying eligible patients, especially those with specific criteria such as family history (for germline testing), or cancer type/staging/tumor characteristics (for somatic testing), OncoLens increases the probability of patients receiving appropriate testing and potential life-saving targeted therapies.
A Case Study
A community cancer center recently deployed OncoLens’ Advanced Patient ID to streamline their review of breast cancer patients who were missed for genetic testing. The Patient ID report found 65% of potentially eligible patients (50 of 76) had no history of germline testing, and specifically one triple-negative breast cancer patient “Susan.”
Susan, a 64-year-old triple-negative breast cancer patient, was identified by the Patient ID report as potentially eligible for genetic testing due to meeting NCCN guidelines and having no previous test results. Upon further review by the care team, Susan initially declined genetic testing due to financial concerns despite NCCN guideline recommendations to test patients with triple negative status and a significant family history of breast cancer. Because she initially declined testing, she was likely missed for any follow up review. This is significant, because biomarker testing can uncover patients with specific mutations who may benefit from targeted therapies such as PARP inhibitors which have demonstrated the potential to reduce disease recurrence by as much as 42%1. Additionally, Susan’s family could miss out on predictive testing, early intervention, and/or risk-reducing options. Through utilizing OncoLens’ Advanced Patient ID, Susan was correctly flagged as eligible for genetic testing and the community center’s social workers are following up with her to provide education and explore testing options.
References
1 Carbognin, L., Sperti, E., Galvano, A., Guzzardo, V., Zambelli, M., Veronese, N., & Bria, E. (2023). Systematic review and meta-analysis of PD-1/PD-L1 inhibitors in combination with chemotherapy for the treatment of advanced or metastatic triple-negative breast cancer. Annals of Oncology, 33(12), 1250-1268. https://www.sciencedirect.com/science/article/pii/S0923753422041655
Latest
